Percutaneous transluminal aortic valve replacement: The CoreValve prosthesis
Open heart surgery with mechanical or porcine bioprosthetic valve replacement is the current gold-standard therapeutic approach for the vast majority of patients with severe aortic valve disease, offering symptomatic relief and improving long-term survival. However, the etiology of aortic stenosis in the Western population is primarily degenerative, and patients are typically elderly with multiple co-morbid conditions which increase surgical risk [1, 2, 3]. In high-risk patients with baseline features such as left ventricular failure, concomitant coronary artery disease, prior bypass graft surgery, chronic obstructive pulmonary disease and/or advanced age, expected operative mortality ranges from 10% to even 50% in high-risk patients subgroups . Moreover, surgery is often not performed in high-risk patients. In the Euro Heart Survey, up to 33% of patients in NYHA functional class III/IV with a single diseased valve were declined for surgery or were never considered as surgical candidates, due to an expected short life expectancy and associated comorbid conditions . alternative techniques for treatment of high-risk patients are therefore needed.
KeywordsAortic Valve Aortic Stenosis Aortic Valve Replacement Transcatheter Aortic Valve Implantation Aortic Valve Stenosis
Unable to display preview. Download preview PDF.
- 1.Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L (1999) Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15(6):816–822CrossRefPubMedGoogle Scholar
- 4.Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24(13):1231–1243CrossRefPubMedGoogle Scholar
- 10.Cribier A, Eltchaninoff H, Borenstein N (2001) Transcatheter implantation of balloon expandable prosthetic heart valves: early results in an animal model. Circulation 104:II552 (abstract)Google Scholar
- 12.Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, Bash A, Nusimovici D, Litzler PY, Bessou JP, Leon MB (2004) Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. JACC 43(4):698–703PubMedGoogle Scholar
- 13.Bauer F, Eltchaninoff H, Tron C, Lesault PF, Agatiello C, Nercolini D, Derumeaux G, Cribier A (2004) Acute improvement in global and regional left ventricular systolic function after percutaneous heart valve implantation in patients with symptomatic aortic stenosis. Circulation 110(11):1473–1476CrossRefPubMedGoogle Scholar
- 14.Grube E, Laborde JC, Zickmann B, Gerckens U, Felderhoff T, Sauren B, Bootsveld A, Buellesfeld L, Iversen S (2005) First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treament of aortic valve stenosis. Catheter Cardiovasc Interv 66(4):465–469CrossRefPubMedGoogle Scholar
- 15.Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B, Iversen S, Stone GW (2006) Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 114(15): 1616–1624CrossRefPubMedGoogle Scholar
- 16.Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, Sauren B, Mohr FW, Walther T, Zickmann B, Iversen S, Felderhoff T, Cartier R, Bonan R (2007) Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second-and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 50(1):69–76. Epub 2007 Jun 6CrossRefPubMedGoogle Scholar
- 18.Piazza N, Grube E, Gerckens U, den Heijer P, Linke A, Luha O, Ramondo A Ussia G, Wenaweser P, Windecker S, Laborde JC, de Jaegere P, Serruys P (2008) Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve ReValving System: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroInterv 4:242–249Google Scholar
- 19.Grube E, Gerckens U (2008) Retrograde transfemoral aortic valve replacement — from early device prototypes to a routine cath lab procedure. Data on CoreValve registry presented at TCT, Washington, 12th–17th October 2008Google Scholar